For stabilization of vaccine preparations, they are lyophilized. The composition of the protective medium is an important parameter affecting the quality of the vaccine after drying. In view of the risk of spreading prion diseases, the use of media containing animal proteins is not recommended. In this study, protective media containing no animal proteins and lyophilization regimen were determined. The optimum lyophilization regimen consisted of three stages: freezing at -70°C, main stage at -35°C, and drying at 24°C. Protective medium containing 4% trehalose or protective medium with 10% sucrose and 5% soy peptone ensured highest stability of the lyophilized vaccine preparation in temperature range of 4-24°C. This can help to overcome possible break in the cold chain, which is important during transporting or storage of vaccine preparations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arshinova OY, Sanarova EV, Lantsova AV, Oborotova NA. Drug synthesis methods and manufacturing technology: Lyophilization of liposomal drug forms (review). Pharm. Chem. J. 2012;46(4):228-234.
Mazurkova NA, Skarnovich MO, Troshkova GP, Shishkina LN. Optimization of freeze-drying process for cultured coldadapted vaccine samples of influenza A/H5N2 virus. Mezhdunar. Zh. Priklad. Fundament. Issled. 2011;(5):98-100. Russian.
Gel’fand AS, Bryzgalova SI, Mel’nikov SJ. Patent RU No. 2290205. Method for preparing live vaccine for influenza prophylaxis. Bull. No. 36. Published December 27, 2006.
EMEA 2001. Questions and answers on bovine spongiform encephalopathies and vaccine. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003715.pdf.
Heikal A, Box K, Rothnie A, Storm J, Callaghan R, Allen M. The stabilisation of purified, reconstituted P-glycoprotein by freeze drying with disaccharides. Cryobiology. 2009;58(1):37-44.
Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep. 2010;125(Suppl. 3):15-26.
WHO. Expert committee on biological standardization. Geneva, 19 to 23 October 2009. WHO recommendations to assure the quality, safety, and efficacy of influenza vaccines (human, live attenuated) for intranasal administration. URL: http://www.who.int/biologicals/areas/vaccines/influenza/Influenza_vaccines_final_14MAY_2010.pdf.
WHO. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season, 26 February 2015. URL: http://www.who.int/influenza/vaccines/virus/recommendations/2015_16_north/en/.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 165, No. 1, pp. 62-66, January, 2018
Rights and permissions
About this article
Cite this article
Dubrovina, I.A., Kiseleva, I.V., Kireeva, E.V. et al. Composition of the Stabilizer and Conditions of Lyophilization for Preserving Infectious Activity of Influenza Virus. Bull Exp Biol Med 165, 52–56 (2018). https://doi.org/10.1007/s10517-018-4097-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-018-4097-7